Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage

Abbott Laboratories (NYSE: ABT | ABT Price Prediction) doesn’t just pay dividends. It grows them. For 52 consecutive years. That’s Dividend King territory, and the streak isn’t in danger.

The company just raised its quarterly dividend to $0.63 in January 2026, a 6.8% increase from the prior $0.59 rate. That puts the annual payout at $2.52 per share with a yield around 1.9%. Not eye-popping, but the safety and growth profile more than compensate.

Cash Flow Covers the Dividend Easily

Abbott generated $6.35 billion in free cash flow in 2024 against $3.84 billion in dividend payments. That’s a free cash flow payout ratio of 60.4%, leaving plenty of room for continued increases. The company paid out $1.03 billion in dividends in Q3 2025 while generating $2.29 billion in free cash flow, a comfortable 45% quarterly payout ratio.

Operating cash flow hit $8.56 billion in 2024, up 18% from 2023’s $7.26 billion. Capital expenditures remain disciplined at around $2.2 billion annually, or roughly 25% of operating cash flow. This leaves substantial cash for dividends, debt reduction, and share buybacks.

A Fortress Balance Sheet

Abbott has been systematically reducing debt. Total debt dropped from $15.3 billion at year-end 2024 to $12.9 billion by Q3 2025, a 15% reduction. The debt-to-equity ratio sits at just 0.25x, down from 0.61x in 2020. Net debt is around $5.4 billion against $11.75 billion in EBITDA, giving a net debt-to-EBITDA ratio under 0.5x. Interest coverage exceeds 68x based on Q3 figures.

Shareholder equity has grown from $32.8 billion in 2020 to $51.0 billion in Q3 2025. Retained earnings stand at $49.1 billion. This is a balance sheet built for dividend sustainability.

Diversification Protects the Dividend

Abbott isn’t dependent on any single product or market. Medical devices grew 12.5% in Q3 2025, led by continuous glucose monitors (FreeStyle Libre at $2 billion quarterly), structural heart devices, and electrophysiology products. Established pharmaceuticals grew 7%, nutrition 4%, and diagnostics rebounded as COVID testing headwinds lapped.

CEO Robert Ford explicitly prioritized the dividend on the Q3 earnings call: “We have been using it in terms of dividend and growing our dividend. We have been using it in terms of share buybacks. We’ve got $3 billion of debt to pay down next year.” Management is comfortable with high single-digit revenue growth and double-digit EPS growth through 2026.

This Dividend Is Fortress-Grade

Dividend Safety Rating: Very Safe

The 60% FCF payout ratio, declining debt, and diversified revenue streams make Abbott’s dividend exceptionally secure. The company has navigated the loss of COVID testing revenue without missing a beat, posting 7.5% organic sales growth in 2025.

I’d be comfortable owning Abbott for income if you value consistent dividend growth over high current yield. The 52-year streak isn’t ending anytime soon. But if you need 4%+ yields today, look elsewhere. Abbott is built for investors who want a dividend that compounds reliably for decades.